Intra-articular administration of recombinant HMGB1 into the knee joints of mice induces destructive arthritis, while administration of monoclonal anti-HMGB1 antibody or the antagonistic box A peptide can ameliorate inflammatory symptoms (3–6). Here, HMGB1 is linked to arthritic joint disease.